ATE194985T1 - Kondensiertes pyrazinderivat - Google Patents

Kondensiertes pyrazinderivat

Info

Publication number
ATE194985T1
ATE194985T1 AT91918943T AT91918943T ATE194985T1 AT E194985 T1 ATE194985 T1 AT E194985T1 AT 91918943 T AT91918943 T AT 91918943T AT 91918943 T AT91918943 T AT 91918943T AT E194985 T1 ATE194985 T1 AT E194985T1
Authority
AT
Austria
Prior art keywords
represent
alkyl
pyrazine derivative
nitro
cycloalkyl
Prior art date
Application number
AT91918943T
Other languages
English (en)
Inventor
Shuichi Sakamoto
Jun-Ya Ohmori
Hirokazu Kubota
Masao Sasamata
Masamichi Okada
Kazuyuki Hidaka
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Application granted granted Critical
Publication of ATE194985T1 publication Critical patent/ATE194985T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT91918943T 1990-11-06 1991-11-01 Kondensiertes pyrazinderivat ATE194985T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP30087990 1990-11-06
JP6959291 1991-01-11
JP13382891 1991-03-29
JP18324891 1991-06-27
PCT/JP1991/001498 WO1992007847A1 (en) 1990-11-06 1991-11-01 Fused pyrazine derivative

Publications (1)

Publication Number Publication Date
ATE194985T1 true ATE194985T1 (de) 2000-08-15

Family

ID=27465151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918943T ATE194985T1 (de) 1990-11-06 1991-11-01 Kondensiertes pyrazinderivat

Country Status (14)

Country Link
US (1) US5283244A (de)
EP (1) EP0556393B1 (de)
JP (1) JP2550456B2 (de)
KR (1) KR0132903B1 (de)
AT (1) ATE194985T1 (de)
AU (1) AU656154B2 (de)
CA (1) CA2095444C (de)
DE (1) DE69132340T2 (de)
DK (1) DK0556393T3 (de)
ES (1) ES2150417T3 (de)
GR (1) GR3034629T3 (de)
HU (2) HU221425B (de)
RU (1) RU2095352C1 (de)
WO (1) WO1992007847A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
ES2313714T3 (es) * 1992-06-22 2009-03-01 The Regents Of The University Of California Antagonistas de receptores de glicina y uso de los mismos.
EP0664807B1 (de) 1992-10-13 1997-09-10 Warner-Lambert Company Chinoxalinderivate als eaa antagonisten
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
DE4340045A1 (de) * 1993-11-24 1995-06-01 Basf Ag Neue Chinoxaline und Arzneimittel daraus
IL112235A (en) * 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
AU688459B2 (en) * 1994-04-08 1998-03-12 Shionogi & Co., Ltd. Oxopyridinylquinoxaline derivative
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
WO1996010023A1 (fr) * 1994-09-27 1996-04-04 Yamanouchi Pharmaceutical Co., Ltd. Derive de 1,2,3,4-tetrahydroquinoxalindione
DE4436852A1 (de) * 1994-10-14 1996-04-18 Basf Ag Pyrrolyl-tetrahydrobenzochinoxalindione, ihre Herstellung und Verwendung
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19532050A1 (de) * 1995-08-31 1997-03-06 Basf Ag Pyrrolyl-tetrahydrochinoxalindione, ihre Herstellung und Verwendung zur Bekämpfung von Krankheiten
GB9605027D0 (en) * 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
IL129394A (en) * 1996-10-24 2002-05-23 Novartis Ag Amino-alkaline phosphonic acids are converted
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors
AP982A (en) * 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
WO1999024434A1 (en) 1997-11-11 1999-05-20 Ono Pharmaceutical Co., Ltd. Fused pyrazine compounds
CN1298704C (zh) * 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
ES2567133T3 (es) 2005-06-23 2016-04-20 Array Biopharma, Inc. Proceso para preparar compuestos de benzoimidazol
MEP23808A (en) * 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
SI2076506T1 (sl) 2007-01-16 2011-01-31 Purdue Pharma Lp Heterociklično substituirani piperidini kot ORL-1 ligandi
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
EP3101018B1 (de) 2007-08-31 2019-03-06 Purdue Pharma L.P. Piperidinverbindungen vom substituierten chinoxalintyp und anwendungen davon
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN116615199A (zh) * 2020-11-26 2023-08-18 株式会社Lg化学 作为二酰基甘油激酶抑制剂的杂环化合物及其用途
EP4403185A1 (de) 2021-09-15 2024-07-24 University of The Ryukyus Pharmazeutische zusammensetzung zur behandlung von kognitivem verfall oder zur behandlung von übergewicht oder adipositas
WO2023042887A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66149B1 (en) * 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
CA2095444A1 (en) 1992-05-07
AU8766691A (en) 1992-05-26
RU2095352C1 (ru) 1997-11-10
EP0556393A1 (de) 1993-08-25
WO1992007847A1 (en) 1992-05-14
GR3034629T3 (en) 2001-01-31
HU211310A9 (en) 1995-11-28
DE69132340T2 (de) 2001-02-08
JP2550456B2 (ja) 1996-11-06
CA2095444C (en) 2001-06-19
HU9301298D0 (en) 1993-09-28
DK0556393T3 (da) 2000-10-16
ES2150417T3 (es) 2000-12-01
HU221425B (en) 2002-10-28
HUT64324A (en) 1993-12-28
DE69132340D1 (de) 2000-08-31
KR0132903B1 (ko) 1998-04-17
EP0556393B1 (de) 2000-07-26
AU656154B2 (en) 1995-01-27
EP0556393A4 (en) 1994-04-13
US5283244A (en) 1994-02-01

Similar Documents

Publication Publication Date Title
ATE194985T1 (de) Kondensiertes pyrazinderivat
IL97403A0 (en) 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them
DE68920556D1 (de) Substituierte Thiazole und ihre Anwendung als Fungizide.
ES2165393T3 (es) Remedio contra la enfermedad de parkinson.
ES2088537T3 (es) Derivados de piranil cianoguanidina.
ES2161713T3 (es) Derivado de metotrexato.
ES2110213T3 (es) Derivado de n-acilglutamina.
DK0591058T3 (da) Ellipticinderivater med antitumoraktivitet
ATE210642T1 (de) 2-substituierte vitamin-d3-derivate
ES2065994T3 (es) Beta-dicetonas substituidas.
DK451389D0 (da) 2-substituerede 4,5-diaryl-thioimidazoler samt farmaceutisk praeparat indeholdende saadanne forbindelser
DE69426620D1 (de) Antidepressiva
ES2140524T3 (es) Derivados de metotrexato.
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
ATE84303T1 (de) Cysteinderivate.
DK0658555T3 (da) Pyridazinonderivater, fremgangsmåder til fremstilling deraf samt anvendelse deraf
ATE177106T1 (de) Ymidothiophosphat-derivat und insektizid, nematozid und akarizid enthalted dasselbe als aktiven bestandteil.
DE60316219D1 (de) Farbphotographisches lichtempfindliches Silberhalogenidmaterial
PL324070A1 (en) Novel compounds of ellipticin, method of obtaining them and pharmaceutical preparations containing such compounds

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee